RFA-DP-23-001: Assessing the Effectiveness of Programs, Policies, or Practices that Affect Social Determinants of Health to Promote Health Equity and Reduce Health Disparities in Chronic Diseases
Closed
This grant is closed. A newer notice from the same program is open now: NIH, CDC and FDA Small Business Innovation Research Grant (Parent SBIR [R43/R44] Clinical Trial Optional) (PA-27-100). Status: Due dates in the notice, expires April 5, 2027. It is in our archive of Centers for Disease Control and Prevention - ERA notices from 2022.
Centers for Disease Control and Prevention - ERA offered grants of up to $1.0 million to any type of organization. It expected to make about 12 awards worth $28.5 million in total. Applications closed on February 23, 2023.
From the official notice on Grants.gov, last changed January 19, 2023. Checked November 7, 2026.
- Award ceiling$1.0 million
- Total funding$28.5 million
- Expected awards12
- Cost sharingNot required
- Funding typeCooperative Agreement
Key dates
| Posted | November 22, 2022 |
|---|---|
| Deadline | February 23, 2023 |
| Archived by Grants.gov | February 24, 2023 |
Who can apply
This opportunity was open to any type of organization.
All 15 applicant types the notice lists
- State governments
- County governments
- City or township governments
- Special district governments
- Independent school districts
- Public and State controlled institutions of higher education
- Native American tribal governments (Federally recognized)
- Public housing authorities/Indian housing authorities
- Native American tribal organizations (other than Federally recognized tribal governments)
- Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
- Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
- Private institutions of higher education
- For profit organizations other than small businesses
- Small businesses
- Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"
For an application to be considered, the application must be responsive to these Special Eligibility Requirements. If your application is incomplete or non-responsive to the special eligibility requirements listed in this section, it will not enter into the review process. Component A: Research Studies to Assess the Impact of Programs, Policies, or Practices that Address SDOH on Chronic Disease-Related Health Disparities 1. Applicants must have continuous access to data sets and/or data systems needed to accomplish study objectives and a minimum study sample size of 10,000 individuals for each priority area selected. 2. Applicants must have approval for unrestricted publication of the study findings, regardless of study outcomes. 3. Applicants may not request funding above the ceiling amount (direct and indirect) listed below: Tier 1: $600,000 Tier 2: $700,000 Tier 3: $800,000 Tier 4: $900,000 Tier 5: $1,000,000 Component B: SDOH Simulation Model Development Applicants must have access to the clinical and real-world data that are needed to develop and validate the simulation model. Applicants may not request funding above the ceiling amount of $1,000,000 (direct and indirect). Component C: Coordinating Center 1. Applicants for Component C must apply for Component A or Component B. 2. Applicants may not request funding above the ceiling amount of $500,000 (direct and indirect).
Is this a realistic fit?
- Past Chronic Diseases: Research, Control, and Prevention awards averaged $651,162; this notice allows up to $1.0 million per award.
- Most of the program's money (35% over five years) went to nonprofits.
- No cost sharing or match is required.
What the grant funds
The purpose of this NOFO is to support rapid, applied research with rigorous study design (i.e., natural experiments, quasi-experimental design studies, simulation modeling, and economic evaluations) to evaluate the impact of ongoing programs, policies, and environmental improvement strategies on SDOH and how these changes in SDOH improve chronic disease outcomes and related health disparities. The funded sites are expected to work together to create a network. This NOFO has three (3) components to achieve the purpose of the program: Component A (Research Studies to Assess Inequities in Addressing Chronic Diseases): The purpose is to support epidemiological research using studies with natural or quasi-experimental designs aimed at identifying and evaluating how inequities in chronic disease outcomes are mitigated by ongoing programs, policies, and environmental improvement strategies targeting SDOH. Component B (Studies to Assess Health and Economic Outcomes and Disparities of Chronic Diseases): The purpose is to support research that will apply a systems science approach to build simulation models of the interplay of SDOH factors and their relationship to chronic disease and health disparities, providing long-term estimates (e.g., 10-, 20-, 30-year) of chronic disease outcomes and disparities in quality-adjusted life-years, and the cost and cost-effectiveness of a policy, program, or strategy. Component C (Coordinating Center): The purpose is to support a coordinating center that provides organizational, logistic, and communication support to enhance the efficiency, productivity, and public health impact of the research centers that are funded under Components A and B. Applicants may apply for Component A or Component B. Applicants for Component C must apply for and be funded for Component A or Component B to be funded for Component C.
Who has won Chronic Diseases: Research, Control, and Prevention grants before
From fiscal 2021 to 2025, Chronic Diseases: Research, Control, and Prevention (93.068) awarded $57.3 million across 88 grant awards, an average of $651,162 per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| New York University | New York | 3 | $5.6 million |
| American College of Rheumatology, Inc | Georgia | 1 | $4.9 million |
| Lupus Foundation of America Inc. | District of Columbia | 1 | $4.8 million |
| National Opinion Research Center | Illinois | 2 | $3.2 million |
| Cicatelli Associates, Inc. | New York | 1 | $3.0 million |
Applying now
This notice no longer takes applications. Apply under the newer notice, PA-27-100, which is open now.
The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.
Questions people ask
Is RFA-DP-23-001 still open?
No. It closed on February 23, 2023. A newer notice is open: PA-27-100, due dates in the notice, expires April 5, 2027.
Who can apply for Assessing the Effectiveness of Programs, Policies, or Practices that Affect Social Determinants of Health to Promote Health Equity and Reduce Health Disparities in Chronic Diseases?
Centers for Disease Control and Prevention - ERA accepted applications from any type of organization. The notice adds further conditions, so read its eligibility section.
What is the deadline for Assessing the Effectiveness of Programs, Policies, or Practices that Affect Social Determinants of Health to Promote Health Equity and Reduce Health Disparities in Chronic Diseases?
Closed February 23, 2023. Applications are no longer accepted; the program's newer notices are on this page when there are any.
How much funding is available?
Awards of up to $1.0 million each. About $28.5 million in total across about 12 awards.
Who has won Chronic Diseases: Research, Control, and Prevention grants before?
The largest recipients over five fiscal years were New York University, American College of Rheumatology, Inc, Lupus Foundation of America Inc. The program made 88 awards worth $57.3 million in that time.
Similar open grants
- Single Source for the Continuation of the Caring for OutPatiEnts after Acute Kidney Injury (COPE-AKI) Scientific and Data Research Center (U01 Clinical Trial Required)
- Single Source for the Continuation of the Epidemiology of Diabetes Interventions and Complications (EDIC) Study Research Center (Collaborative U01 Clinical Trial Not Allowed)
- Data Coordinating Center for the Aging and Alzheimer’s Disease Mouse Brain Atlas (AD-MBA) (U24 Clinical Trial Not Allowed)
- Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required)
- Advanced Development and Validation of Emerging Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)
- Early-Stage Innovative Technology Development for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)